PLAY PODCASTS
Extending the Reach of Targeted Therapy for Hormone Receptor-Positive Advanced Breast Cancer

Extending the Reach of Targeted Therapy for Hormone Receptor-Positive Advanced Breast Cancer

Journal of Clinical Oncology (JCO) Podcast · Hope S. Rugo

April 17, 20189m 18s

Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

This podcast discusses a phase II trial evaluating the combination of everolimus and fulvestrant compared to fulvestrant alone in pretreated hormone receptor-positive metastatic breast cancer in terms of context within the current hormone treatment environment and toxicity management.

Read the related article Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102" on JCO.org